Skip to main content
Linvoseltamab for Relapsed/Refractory Multiple Myeloma: Results from IMS 2023 With Madhav Dhodapkar, MD
Keira Smith
Expert Analysis
At the International Myeloma Society (IMS) 2023 Annual Meeting and Exposition, Dr. Madhav Dhodapkar, Director of the Cancer Center at Emory University, presented the results of the LINKER-MM1 trial of linvoseltamab for relapsed/refractory multiple myeloma. Here, he further delves into the efficacy of linvoseltamab observed in the trial and its projected place in the treatment landscape.  
World Cancer Research Day With Samuel Kareff, MD, MPH; Maria Badillo, RN; Matthew Hadfield, DO; and Alankrita Taneja, MD
Keira Smith
Expert Analysis
In honor of World Cancer Research Day, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share their passions for cancer research, discuss the recent and upcoming progress in their respective areas of study, and raise awareness for the tireless efforts being undertaken to advance cancer research.  
Bosutinib Approved for Pediatric Patients With Chronic Myelogenous Leukemia
Lyn Brook
FDA Updates
The FDA has approved bosutinib (Bosulif®, Pfizer) for treatment of pediatric patients with newly diagnosed or resistant/intolerant to prior therapy chronic phase (CP) Philadelphia chromosome (Ph)–positive chronic myelogenous leukemia (CML). In addition, the FDA has approved a new capsule dosage available as 50 mg and 100 mg.   Why it matters: ...
Twice Weekly, Biweekly, or Somewhere in Between? Updates on Dosing Schedules in Multiple Myeloma With Rahul Banerjee, MD, FACP, and Gurbakhash Kaur, MD
Keira Smith
Expert Analysis
In honor of Blood Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Dr. Rahul Banerjee sat down with Gurbakhash Kaur, an Assistant Professor of Medicine at the University of Texas Southwestern Medical Center, to discuss updates and the advantages and disadvantages of different dosing schedules for treating multiple myeloma.  
The Rise of Immunotherapy: Considerations to Ensure Optimal Management With Matthew Hadfield, DO
Keira Smith
Expert Analysis
In this Oncology Data Advisor Fellows Forum Interview, Dr. Matthew Hadfield, third-year Hematology/Oncology Fellow at Brown University, shares a comprehensive timeline of the history of immunotherapy and its emerging role in cancer treatment. Additionally, he shares considerations for the differential diagnosis of immunotherapy-related adverse events, timely management for providing optimal efficacy outcomes, and the importance of keeping immunotherapy-related toxicities on the radar for clinicians of all specialties and types of practice.  
Melphalan for Liver-Directed Treatment of Uveal Melanoma With Richard Carvajal, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Melphalan for Liver-Directed Treatment of Uveal Melanoma With Richard Carvajal, MD Recently, the FDA approved melphalan for liver-directed treatment of uveal melanoma. In this interview, Oncology Data Advisor Editorial Board member Dr. Richard Carvajal, Deputy Physician-in-Chief and Director of Medical Oncology a...
Melphalan for Liver-Directed Treatment of Uveal Melanoma With Richard Carvajal, MD
Lyn Brook
Expert Analysis
Recently, the FDA approved melphalan for liver-directed treatment of uveal melanoma. In this interview, Oncology Data Advisor Editorial Board member Dr. Richard Carvajal, Deputy Physician-in-Chief and Director of Medical Oncology at Northwell Health Cancer Institute in New York, discusses the approval and the trial that led to it, as well as share ...
Prostate Cancer Awareness Month With Ulka Vaishampayan, MD
Lyn Brook
Expert Analysis
Oncology Data Advisor® · Prostate Cancer Awareness Month With Ulka Vaishampayan, MD In honor of Prostate Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Ulka Vaishampayan, Professor of Internal Medicine at the University of Michigan Rogel Cancer Center, sat down to discuss the importance of bringing awareness to pros...
Confronting Knowledge Gaps in Rare Hematologic Malignancies
Lyn Brook
Practice Patterns
In the beginning of 2022, i3 Health and Oncology Data Advisor hosted ODACon: A Rare Hematologic Malignancies Symposium, a live, virtual symposium which provided five educational activities that challenged knowledge gaps experienced by clinicians regarding hematologic malignancies, including acute lymphoblastic leukemia (ALL), Hodgkin lymphoma (HL),...
Raising Awareness of Prostate Cancer in Transgender Women With Farnoosh Nik-Ahd, MD, and Stephen Freedland, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Raising Awareness of Prostate Cancer in Transgender Women: Farnoosh Nik-Ahd and Stephen Freedland This interview in honor of Prostate Cancer Awareness Month features Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, and Dr. Farnoosh Nik-Ahd, Urology Resident at the University of California, San Francisco (UCSF), discussing the risks and incidence of prostate cancer in transgender women. Dr. Nik-Ahd shares the inspiration for her recent first-author study, Prostate Cancer Is Not Just a Man's Concern, the results that she and her team found, and their implications for prostate cancer screening and diagnosis standards for transgender women.  
Prostate Cancer Awareness Month With Ulka Vaishampayan, MD
Keira Smith
Expert Analysis
In honor of Prostate Cancer Awareness Month, Oncology Data Advisor Editorial Board Member Ulka Vaishampayan, Professor of Internal Medicine at the University of Michigan Rogel Cancer Center, sat down to discuss the importance of bringing awareness to prostate cancer, up-to-date diagnostic techniques, and updates in therapeutic selection and treatment.  
Raising Awareness of Prostate Cancer in Transgender Women With Farnoosh Nik-Ahd, MD, and Stephen Freedland, MD
Keira Smith
Expert Analysis
This interview in honor of Prostate Cancer Awareness Month features Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, and Dr. Farnoosh Nik-Ahd, Urology Resident at the University of California, San Francisco (UCSF), discussing the risks and incidence of prostate cancer in transgender women. Dr. Nik-Ahd shares the inspiration for her recent first-author study, Prostate Cancer Is Not Just a Man's Concern, the results that she and her team found, and their implications for prostate cancer screening and diagnosis standards for transgender women.  
Appendix Cancer Awareness Month With Thomas Abrams, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Appendix Cancer Awareness Month With Thomas Abrams, MD In honor of Appendix Cancer Awareness Month this August, Dr. Thomas Abrams, Editor-in-Chief of Oncology Data Advisor and Assistant Professor of Medicine at Harvard Medical School, sat down to explain the different subtypes and presentations of appendix cancer, factors he takes into consideration when making treatment decisions, and the messages he hopes to convey to both clinicians and patients with the goal of raising awareness for this rare disease.  
Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD Epcoritamab, a bispecific CD20-directed CD3 T-cell engager, is currently being investigated in numerous settings for patients with non-Hodgkin lymphomas. Recently, results were presented at the European Hematology Association (EHA) Congress for Cohorts 2A and 2B of the phase 1/2 EPCORE NHL-2 trial, which is investigating an epcoritamab combination for patients with relapsed/refractory follicular lymphoma. In this interview, Dr. Reid Merryman, an Attending Physician at Dana-Farber Cancer Center and one of the study's investigators, discusses the significance of these results and the efficacy of epcoritamab across the various tumor types being studied.  
Appendix Cancer Awareness Month With Thomas Abrams, MD
Keira Smith
Expert Analysis
In honor of Appendix Cancer Awareness Month this August, Dr. Thomas Abrams, Editor-in-Chief of Oncology Data Advisor and Assistant Professor of Medicine at Harvard Medical School, sat down to explain the different subtypes and presentations of appendix cancer, factors he takes into consideration when making treatment decisions, and the messages he hopes to convey to both clinicians and patients with the goal of raising awareness for this rare disease.  
Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma with Kohei Shitara, MD
Keira Smith
Expert Analysis
Oncology Data Advisor® · Spotlighting Zolbetuximab for Gastric/Gastroesophageal Junction Adenocarcinoma: Kohei Shitara, MD In this interview from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Kohei Shitara, a Medical Oncologist at the National Cancer Center Hospital East in Japan, discusses his two abstracts investigating the efficacy of zolbetuximab in gastric cancers.  
Melphalan Approved for Liver-Directed Treatment for Uveal Melanoma
Lyn Brook
FDA Updates
The FDA has approved melphalan for injection (Hepzato Kit™/Hepatic Delivery System), containing melphalan (Hepzato™, Delcath Systems, Inc.) as a liver-directed treatment for patients with uveal melanoma with unresectable hepatic metastases affecting ≤50% of the liver. This treatment is permitted for those with no extrahepatic disease, or extrahepat...
Elranatamab-bcmm Granted Accelerated Approval for Multiple Myeloma
Lyn Brook
FDA Updates
The FDA granted accelerated approval to elranatamab-bcmm (Elrexfio™, Pfizer, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody. Elranatamab-bcmm is a bispe...
Niraparib and Abiraterone Acetate Plus Prednisone Approved for BRCA-Mutated Metastatic CRPC
Lyn Brook
FDA Updates
The FDA has approved the fixed dose combination of niraparib and abiraterone acetate (Akeega™, Janssen Biotech), plus prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (CRPC), as identified by an FDA-approved test.   Why it matters: "Metastatic CRPC remains a l...
Talquetamab-tgvs Granted Accelerated Approval for Relapsed/Refractory Multiple Myeloma
Lyn Brook
FDA Updates
The FDA has granted accelerated approval to talquetamab-tgvs (Talvey™, Janssen Biotech, Inc.) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.   Why it matters: ...